$0.12
(0.52%)
0.72%
Add to watchlist
Create an alert
Stocks and Shares ISAZymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Company Information
About this company
Key people
Kenneth H. Galbraith
Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
Mark Hollywood
Chief Operating Officer, Executive Vice President
Laura O'Connor
Senior Vice President, Chief Human Resources Officer
Jeffrey Smith
Executive Vice President, Chief Medical Officer
Bijal Desai
Senior Vice President - Finance
Lindsey Foulkes
Senior Vice President - Corporate Development and Strategy
Scott Platshon
Acting Chief Investment Officer
Paul A. Moore
Chief Scientific Officer
Susan M. Mahony
Lead Independent Director
Brian N. Cherry
Director
Carlos E. Campoy
Independent Director
Alessandra Cesano
Independent Director
Gregory A. Ciongoli
Independent Director
Click to see more
Key facts
- Shares in issue74.84m
- EPICZYME
- ISINUS98985Y1082
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.67bn
- Employees263
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.